At 3.3% CAGR Fibromyalgia Treatment Market To Hit US$ 3,607.3 Mn By 2026 – Coherent Market Insights

SEATTLE, March 31, 2021, (PHARMIWEB) — Fibromyalgia is a common and complex chronic pain disorder that causes musculoskeletal pain, fatigue, and localized tenderness affecting individuals mentally, physically, and socially. Fibromyalgia is mainly caused due to genetic conditions, however the actual cause is still unknown. The most common symptoms of fibromyalgia are fatigue, sleeping problems, chronic muscle pain, and tender points. An individual with fibromyalgia can also have symptoms such as headaches, poor concentration, and depression. Fibromyalgia symptoms might accumulate with time or it can be caused by some external factors. Fibromyalgia treatments include therapy, medications, regular aerobic exercise, stress reduction, and others. Furthermore, for treatment of fibromyalgia, antidepressants or pain medications are prescribed to treat depression, anxiety, pain, and fatigue.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1691

A robust pipeline of novel drugs in clinical trial phase for treatment of fibromyalgia is likely to favour the market growth.

Market players are focusing on active research and development in order to introduce new products in the market and increase treatment options. Approval and launch of novel fibromyalgia treatment drugs is expected to significantly support fibromyalgia treatment market growth over the forecast period.

For instance, manufacturers such as Aptinyx, Inc., Prismic Pharmaceuticals, Inc., Innovative Med Concepts, Inc., Intec Pharma Ltd., Astellas Pharma, Inc., and others have pipeline drugs indicated for the treatment of fibromyalgia.

Many such drugs are in phase 2 and phase 3 of clinical trials with commercialization potential. For instance, Astellas Pharma, Inc. has ASP0819 in phase 2 and IMC-1 received the Fast Track designation from the U.S. FDA in 2016.

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://bit.ly/3lXMBIs

The global fibromyalgia treatment market size was valued at US$ 2,778.6 Mn in 2018 and is expected to witness a CAGR of 3.3% during the forecast period (2018 – 2026).

Figure 1. Global Fibromyalgia Treatment Market Share (%), By Drug Class, 2018-2026

Source: Coherent Market Insights Analysis (2019)

North America is expected to hold dominant position in the global fibromyalgia treatment market over the forecast period

North America fibromyalgia treatment market is expected to hold the largest market share over the forecast period in the global fibromyalgia treatment market owing to potential customer base, new product launches, and presence of leading manufacturers in the region.

Generic manufacturers such as Teva Pharmaceutical Industries Ltd., Mylan N.V., and others have launched generic drugs in North America which has supported growth of the market.

Although, the overall market size has decreased due to patent loss and subsequent generic launches at low prices For instance, two products, Savella and Lyrica, still have patent protection up to 2021 and June 2019 respectively.

View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/fibromyalgia-treatment-market-to-surpass-us-36073-mn-threshold-by-2026-1385

Originators of branded drugs suffered major revenue loss due to patent expiry (Cymbalta) in 2013. However, arrival of various generic versions has led to an increase in the adoption rate due to lower prices, thereby driving the fibromyalgia treatment market growth.

Several manufacturers such as Aptinyx, Inc., Prismic Pharmaceuticals, Inc., and Innovative Med Concepts, Inc. have drugs in the pipeline for treatment of fibromyalgia.

Figure 2. Global Fibromyalgia Treatment Market Share (%) Analysis, By Region, 2026

Source: Coherent Market Insights Analysis (2019)

Restraints

Currently, three U.S. Food & Drug Administration (FDA) approved medications are available in the market which include Cymbalta, Lyrica, and Savella. Other medications such as certain antidepressants (amitriptyline, fluoxetine, and others), antiepileptic drugs (gabapentin), and other treatments are used as an off-label medication for the treatment of fibromyalgia. Opioids are highly used in management of various pain conditions as well as fibromyalgia. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2012, around 260 million prescriptions were issued for opioid pain medication in the U.S. by healthcare providers, an increase of 300% as compared to the number of prescriptions written for the same in 1999. Moreover, prescriptions per capita increased by 7.3% from 2007 to 2012.

This factor is expected to affect growth of the global fibromyalgia treatment market up to certain extent along with the fact that there is no curative treatment available for fibromyalgia.

Market Opportunity

Currently, there are limited number of approved treatment options for fibromyalgia. Several manufacturers have potential candidates in the pipeline (some in late stages as well). Hence, new players in the market also have opportunity to develop new drug candidates for treatment of fibromyalgia.

Another opportunity is present in terms of generic drug manufacturing, as two of the drugs are expected to lose patent protection over the forecast period (Lyrica in 2019 and Savella in 2021, 2023, and 2029). Patent loss may be a restraint for the market, however, there is certainly an opportunity for generic manufacturers.

Key players operating in the fibromyalgia treatment market include Eli Lilly and Company, Pfizer, Inc., Novartis AG, Allergan plc., Sun Pharmaceutical Industries Ltd., Aptinyx, Inc., Prismic Pharmaceuticals, Inc., Innovative Med Concepts, Inc., Intec Pharma Ltd., and Astellas Pharma Inc.

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837